Approval hinged on rigorous testing, including an investigational device exemption study confirming its safety and efficacy, according to a news release. Research has found TOPS was superior over transforaminal lumbar interbody fusion when addressing degenerative spondylolisthesis with stenosis.
“With FDA approval now secured, our priority shifts to ensuring access to the TOPS System for the countless individuals living with spinal stenosis and spondylolisthesis,” CEO Ron Sacher said in the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
